Voyager Therapeutics
VYGR | NASDAQ
$1.63
-$0.10 (-5.78%)
At close: Nov 16, 2026, 4:00 PM ET
$1.62
-$0.01 (-0.61%)
After-hours:
Nov 16, 2026, 7:39 PM ET
-5.78%
(1D)No price chart data available for 1D timeframe.
Rating
33
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #716/1021 (Top 70%)
Key Statistics
Market Data
Market Cap $101.43M
1D Range
1.62 1.74
52W Range
1.62 5.00
Valuation (TTM)
PE -0.94
PB 0.75
EV/EBITDA -0.33
Valuation (NTM)
Forward PE N/A
Forward PEG 0.04
Price Target $18.00
Cash Flow
FCF Yield -108.3%
SBC Adj. FCF Yield -119.2%
SBC Impact -10.1%
Margins
Gross Margin 100.0%
Operating Margin -344.9%
FCF Margin -437.4%
Growth (CAGR)
Revenue 3Y | 5Y -45.9% |
9.6%
Dil EPS 3Y | 5Y -115.2% |
-123.9%
FCF 3Y | 5Y -47.3% |
-136.3%
Returns
ROA -59.0%
ROE -63.4%
ROIC -67.8%
Financial Health
Net Cash
$76.3M
Current Ratio 6.81
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, ...
Sector Healthcare
Industry Biotechnology
Employees 141
IPO Date Nov 11, 2015
Website www.voyagertherapeutics.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 5, 2026
EPS
-$0.4
Beat +4.49%
YoY:
+14.89% REV
$4.01M
Miss -36.79%
YoY:
-69.97%Next Earnings
Mar 8, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$18.00
Upside
+1004.29%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove VYGR